2023
The Choice of Anticoagulant at First Recurrence Does Not Alter the Risk for the Second Recurrence
Muradashvili T, Restrepo V, Alameddine D, Soliman S, Feinn R, Chaar C, Lee A, Pine A. The Choice of Anticoagulant at First Recurrence Does Not Alter the Risk for the Second Recurrence. Blood 2023, 142: 5540. DOI: 10.1182/blood-2023-191084.Peer-Reviewed Original ResearchFirst VTE recurrenceDeep venous thrombosisFirst venous thromboembolismRecurrent VTE eventsVTE recurrenceVenous thromboembolismPulmonary embolismAnticoagulation regimenVTE eventsAnticoagulant regimenFirst recurrenceINR targetSecond recurrenceExact testFirst recurrent venous thromboembolismInferior vena cava atresiaLarge tertiary academic hospitalUnprovoked first venous thromboembolismMajor public health hazardDifferent anticoagulant agentsInterruption of anticoagulationCardiovascular risk factorsMay-Thurner syndromePatients 18 yearsRecurrent venous thromboembolism
2022
Monogenic and Polygenic Contributions to Venous Thromboembolism (VTE) and Splanchnic Thrombosis in Patients (pts) with Pancreatic Cancer (PC)
Nassar A, Groha S, El-am E, Bejjani A, Zarif T, Mouhieddine T, Alaiwi S, Adib E, Ng K, Connors J, Lee A, Gusev A. Monogenic and Polygenic Contributions to Venous Thromboembolism (VTE) and Splanchnic Thrombosis in Patients (pts) with Pancreatic Cancer (PC). Blood 2022, 140: 5525-5526. DOI: 10.1182/blood-2022-163804.Peer-Reviewed Original Research
2021
Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 Thrombosis
Madeeva D, Borges K, Shallow M, Juthani P, Wang S, Gupta A, Chun H, Lee A, Pine A. Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 Thrombosis. Blood 2021, 138: 777. PMCID: PMC8701622, DOI: 10.1182/blood-2021-153959.Peer-Reviewed Original ResearchSerum amyloid ACOVID-19 patientsVenous thromboembolismCOVID-19 infectionLipocalin-2Thromboembolic eventsThromboembolic complicationsPentraxin 3Complement factors C2COVID-19Lower extremity Doppler ultrasoundTissue factorComplement activationCell adhesion molecule-1Pathogenesis of thromboembolismInstitutional review board approvalChest CT angiographyAdhesion molecule-1Endothelial cell adhesion molecule-1Novel therapeutic strategiesSodium citrate tubesReview board approvalClassical complement pathwayRadiologic confirmationICU patients
2019
Whole-Exome Sequencing in Evaluation of Thrombophilia: Characterization of Novel Genetic Variants
Gu S, Shevell L, Tormey C, Rinder H, Lee A. Whole-Exome Sequencing in Evaluation of Thrombophilia: Characterization of Novel Genetic Variants. American Journal Of Clinical Pathology 2019, 152: s35-s35. DOI: 10.1093/ajcp/aqz112.066.Peer-Reviewed Original ResearchWhole-exome sequencingMultiple sequence alignment analysisVenous thromboembolismGenetic variantsSequence alignment analysisDisease-causing genetic variantsVon Willebrand factorRegions of proteinsNovel genetic variantsNext-generation sequencing studiesAmino acid substitutionsGenetic factorsNovel VUSAlignment analysisMajority of VTESequencing studiesAcid substitutionsSilico mutagenesisConformational changesEvaluation of thrombophiliaDeep venous thrombosisNonsynonymous variantsProthrombin gene mutationFactor V LeidenEnzymatic activity
2018
Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment
Juthani P, Ahmed D, Ahmed O, Bona R, Neparidze N, Lee A. Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment. Blood 2018, 132: 5810. DOI: 10.1182/blood-2018-99-119418.Peer-Reviewed Original ResearchVenous thromboembolismVTE patientsPrevention of VTESymptoms of VTERecurrent venous thromboembolismDeep venous thrombosisRandomized control trialLong-term managementOnline health educationMost patientsPulmonary embolismAdult patientsHospitalized patientsOncology providersVenous thrombosisHematology clinicCancer HospitalMedication adherenceOutpatient clinicTreatment optionsPatient interviewsPhysician interviewsMalignant hematologyPatient educationPreventable deaths
2017
Anticoagulation for Proximal Deep Vein Thrombosis
Lee A, Lee E. Anticoagulation for Proximal Deep Vein Thrombosis. 2017, 299-313. DOI: 10.1007/978-3-319-65226-9_23.Peer-Reviewed Original ResearchDeep vein thrombosisVenous thromboembolismPulmonary emboliVein thrombosisProximal deep vein thrombosisMonths of anticoagulationProvoked venous thromboembolismUnprovoked venous thromboembolismEstimates of recurrenceLow recurrence riskRisk prediction modelExtended anticoagulationSurveillance ultrasonographyVTE eventsSuch patientsD-dimerSignificant morbidityThrombotic riskRisk factorsThrombophilia testingHigh riskAnticoagulationThrombosisRecurrenceRiskWhole-exome sequencing in evaluation of patients with venous thromboembolism
Lee EJ, Dykas DJ, Leavitt AD, Camire RM, Ebberink E, García de Frutos P, Gnanasambandan K, Gu SX, Huntington JA, Lentz SR, Mertens K, Parish CR, Rezaie AR, Sayeski PP, Cromwell C, Bar N, Halene S, Neparidze N, Parker TL, Burns AJ, Dumont A, Yao X, Chaar CIO, Connors JM, Bale AE, Lee AI. Whole-exome sequencing in evaluation of patients with venous thromboembolism. Blood Advances 2017, 1: 1224-1237. PMID: 29296762, PMCID: PMC5728544, DOI: 10.1182/bloodadvances.2017005249.Peer-Reviewed Original ResearchWhole-exome sequencingVenous thromboembolismStudy patientsThrombophilia panelVTE patientsHeritable thrombophiliaThrombophilia testingDisease-causing genetic variantsEvaluation of patientsControl patientsThrombophilia mutationsProtein modelingThrombotic historyProtein structurePatientsThrombophilia genesVTE pathogenesisWES variantsUnknown significanceThrombophiliaGenetic variantsGenesPrior reportsSequencingThromboembolism
2015
Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey
Lee E, Smith B, Merrey J, Lee A, Podoltsev N, Barbarotta L, Litzow M, Prebet T, Luger S, Gore S, Streiff M, Zeidan A. Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey. Blood 2015, 126: 4455. DOI: 10.1182/blood.v126.23.4455.4455.Peer-Reviewed Original ResearchECOG-ACRIN Cancer Research GroupVTE prophylaxisEvidence-based guidelinesVenous thromboembolismCancer Research GroupAcute leukemiaAL patientsConsolidation therapyPharmacologic prophylaxisVTE preventionPlatelet countPractice patternsJohns Hopkins Institutional Review BoardWeb-based surveyLimited high-quality studiesPharmacologic VTE prophylaxisVTE prophylaxis practicesVenous thromboembolism prophylaxisSequential compression devicesPlatelet count thresholdQuestion web-based surveyHigh-quality studiesInstitutional review boardProphylactic anticoagulationThromboembolism prophylaxisClinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy
Stutsky M, Reardon D, Lee A. Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy. Blood 2015, 126: 3275. DOI: 10.1182/blood.v126.23.3275.3275.Peer-Reviewed Original ResearchAnti-Xa levelsAnti-Xa monitoringLMWH doseLow molecular weight heparin therapyAbnormal body mass indexActions of providersWeight heparin therapyAcute kidney injuryChronic kidney diseaseHigh-risk patientsRetrospective chart reviewLong-term therapyBody mass indexClinical practice patternsFactor Xa inhibitorsNon-therapeutic levelsEnoxaparin doseHematology consultHeparin regimensTherapeutic LMWHHeparin therapyKidney injuryLMWH therapyRenal dysfunctionVenous thromboembolism